Expert Opinion on Drug Discovery

Expert Opinion on Drug Discovery is a monthly peer-reviewed journal published by Taylor and Francis, founded in 2006 and indexed in MEDLINE, SCIE and Scopus, with a 2025 impact factor of 7.3（Expert Opinion on Drug Discovery）是由（Taylor & Francis）出版的月刊同行评审期刊，2006 年创刊，被 MEDLINE、SCIE 与 Scopus 收录，2025 年影响因子为 7.3。

Scope

• Chemoinformatics and bioinformatics approaches to drug discovery用于药物发现的化学信息学与生物信息学方法。
• Assay development and novel screening technologies分析方法开发与新型筛选技术。
• In vitro and in vivo models for target validation and lead optimisation用于靶点验证与先导化合物优化的体外与体内模型。
• Structure-based drug design and systems biology基于结构的药物设计与系统生物学。
• Drug case histories and critical reviews that carry an expert opinion on future directions药物研发案例史与评述，须附作者对未来方向的专家意见。

History

• The journal was launched in June 2006 as part of the Expert Opinion series from Informa Healthcare该刊 2006 年 6 月创刊，属于 Informa Healthcare 旗下的 Expert Opinion 系列。
• Its founding publisher Informa Healthcare was later folded into the Taylor and Francis group, now part of Informa其创刊出版方 Informa Healthcare 后并入（Taylor & Francis）集团，现隶属 Informa 集团。
• It has issued twelve issues a year since launch and has never changed its title自创刊起每年出版 12 期，刊名始终未变。
• It is abstracted in MEDLINE, Embase, SCIE and Scopus该刊被 MEDLINE、Embase、SCIE 与 Scopus 收录。

Editors

• The editor-in-chief is David Janero of Northeastern University in Boston现任主编为美国波士顿 Northeastern University 的 David Janero。
• It is part of the Expert Opinion collection of review journals该刊属于 Expert Opinion 系列综述期刊。
• Manuscripts are double-anonymized peer reviewed, and a pre-submission enquiry with the commissioning editor is encouraged稿件采用双匿名同行评审，并鼓励作者事先向约稿编辑进行投稿咨询。
• It is hybrid open access under the Taylor and Francis Open Select programme该刊为混合开放获取，纳入（Taylor & Francis）Open Select 计划。